Genmab AS Cash Flow-to-Debt Ratio
Genmab AS cash flow-to-debt ratio. Genmab AS (GMAB) has a Cash Flow-to-Debt Ratio of 0.04x as of December 2025, meaning its operating cash flow of $300.34 Million could theoretically repay 0% of its total liabilities ($7.01 Billion) in one year. Check Genmab AS (GMAB) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Genmab AS (2002–2025)
Cash flow-to-debt ratio of Genmab AS from 2002 to 2025. Historical debt coverage capacity for Genmab AS across 24 annual periods. Check total reinvestment intensity of Genmab AS to assess the company's total reinvestment commitment from operating cash flow.
Genmab AS Cash Flow-to-Debt Ratio by Year (2002–2025)
Genmab AS cash flow-to-debt ratio by year from 2002 to 2025. Year-by-year debt coverage analysis for Genmab AS. For the full cash flow conversion analysis, see Genmab AS operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.17x | $1.19 Billion | $7.01 Billion | ▼ -80.1% |
| 2024 | 0.85x | $7.77 Billion | $9.11 Billion | ▼ -57.5% |
| 2023 | 2.01x | $7.38 Billion | $3.68 Billion | ▲ +45.5% |
| 2022 | 1.38x | $3.91 Billion | $2.84 Billion | ▲ +50.5% |
| 2021 | 0.92x | $2.23 Billion | $2.43 Billion | ▼ -71.2% |
| 2020 | 3.18x | $6.43 Billion | $2.02 Billion | ▲ +163.0% |
| 2019 | 1.21x | $1.33 Billion | $1.10 Billion | ▼ -46.8% |
| 2018 | 2.27x | $1.01 Billion | $446.64 Million | ▼ -52.7% |
| 2017 | 4.80x | $1.59 Billion | $330.75 Million | ▲ +503.3% |
| 2016 | 0.80x | $327.72 Million | $411.54 Million | ▲ +6.3% |
| 2015 | 0.75x | $311.45 Million | $415.83 Million | ▲ +370.7% |
| 2014 | 0.16x | $132.67 Million | $833.74 Million | ▲ +233.3% |
| 2013 | -0.12x | $-128.00 Million | $1.07 Billion | ▼ -320.5% |
| 2012 | 0.05x | $70.92 Million | $1.31 Billion | ▲ +113.4% |
| 2011 | -0.41x | $-437.23 Million | $1.08 Billion | ▼ -312.0% |
| 2010 | 0.19x | $268.17 Million | $1.40 Billion | ▲ +131.0% |
| 2009 | -0.62x | $-570.06 Million | $924.34 Million | ▼ -28.6% |
| 2008 | -0.48x | $-513.33 Million | $1.07 Billion | ▼ -202.0% |
| 2007 | 0.47x | $505.90 Million | $1.08 Billion | ▲ +124.4% |
| 2006 | -1.93x | $-379.62 Million | $197.05 Million | ▼ -132.4% |
| 2005 | -0.83x | $-208.64 Million | $251.66 Million | ▲ +79.5% |
| 2004 | -4.04x | $-367.70 Million | $90.92 Million | ▼ -25.3% |
| 2003 | -3.23x | $-302.36 Million | $93.67 Million | ▼ -92.6% |
| 2002 | -1.68x | $-308.32 Million | $183.97 Million | — |